Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects.
about
Immunogenicity and PK/PD evaluation in biotherapeutic drug development: scientific considerations for bioanalytical methods and data analysis.Romiplostim dose response in patients with immune thrombocytopenia.Romiplostim: a review of its use in immune thrombocytopenia.Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia.Mathematical model of platelet turnover in thrombocytopenic and nonthrombocytopenic preterm neonatesPharmacodynamic model for chemoradiotherapy-induced thrombocytopenia in mice.Multicenter, prospective study to evaluate the efficacy of biweekly romiplostim administration in patients with immune thrombocytopenia.Platelet Dynamics in Peritoneal Carcinomatosis Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal OxaliplatinDevelopment of Romiplostim for Treatment of Primary Immune Thrombocytopenia From a Pharmacokinetic and Pharmacodynamic Perspective.Normal and pathological dynamics of platelets in humans.Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor.Interpretation of transit compartments pharmacodynamic models as lifespan based indirect response modelsComparative performance of cell life span and cell transit models for describing erythropoietic drug effectsDose correction for the Michaelis-Menten approximation of the target-mediated drug disposition model.Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575.Romiplostim dose-response in patients with myelodysplastic syndromesExpression, purification and biological activity assessment of romiplostim biosimilar peptibodyA mathematical model of the effect of immunogenicity on therapeutic protein pharmacokinetics.Pharmacokinetics and pharmacodynamics of pegfilgrastim.Lifespan based indirect response models.The utility of modeling and simulation approaches to evaluate immunogenicity effect on the therapeutic protein pharmacokinetics.Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides.Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents.Modeling of delays in PKPD: classical approaches and a tutorial for delay differential equations.Pharmacodynamic models of age-structured cell populations.A cell-level model of pharmacodynamics-mediated drug disposition.A Tutorial on Target-Mediated Drug Disposition (TMDD) Models.Bioanalytical method validation: concepts, expectations and challenges in small molecule and macromolecule--a report of PITTCON 2013 symposiumRelationship between absolute neutrophil count profiles and pharmacokinetics of DA-3031, a pegylated granulocyte colony-stimulating factor (pegylated-G-CSF): a dose block-randomized, double-blind, dose-escalation study in healthy subjects.Bioanalytical considerations in the comparability assessment of biotherapeutics.Pharmacokinetic and pharmacodynamic modeling of romiplostim in animals.Pharmacokinetic-pharmacodynamic modelling of neutrophil response to G-CSF in healthy subjects and patients with chemotherapy-induced neutropenia.
P2860
Q30716340-8FB5B72D-441C-4A37-92CB-A652EC768271Q33398730-69701ACC-06F9-4510-82DC-886C198CF709Q33399598-4FE3B5E3-C883-4727-A273-3F1536A22217Q33406932-09395C5A-8FD4-4068-BCB1-6637D92AFCA3Q33418500-9BD7F2B3-3FC0-4DFE-AF36-AD1973FE5490Q33425648-6491DB06-3FEE-4535-8ED1-807FC673DCBEQ33427147-6BC6F44A-60AC-4C64-81D1-B3F2A9F7AF3EQ33427607-3CEE7556-F652-4603-BD1D-0F960AA0022FQ33431320-09AC907D-AEB8-4136-8689-4808566125D2Q33440808-DDDD83D0-C123-44E0-818A-33F0F7F60051Q33655344-A38D630F-059B-4B6A-9F6A-4058512B3D3FQ35226129-4C433332-0623-4F6F-8132-B0635DD55E52Q35595803-649B52FE-0588-4B3F-8E5E-98409EC9EDEBQ36185667-371833D0-68A1-4410-8B1A-549CEDCDBB64Q36354544-68FDA423-4834-4FBB-BF85-20758DEB2CD8Q36948110-08DE42B1-2602-4346-B825-A96D6952AEBFQ37084683-6979ECC7-16BE-4324-9C26-C96E6F6E24F9Q37207825-EFB04E75-876E-44CC-AF8D-22DA5A494370Q37860299-A4B31FA5-1BBA-464D-84A7-1EDD0B3CEC12Q37972792-AFC38B6D-5596-43BB-8813-B1A99E7FF2DEQ38058750-38387C3E-CBC1-466C-B60F-276C54401633Q38110433-7A7C66FD-A03F-4F25-BD8B-F7270DCA50A4Q38126361-08F20944-BBCB-4B7F-96D9-CB4E5552A16DQ38241696-A9633C07-5AFD-41B5-9133-8C38C9D2BC87Q38588105-21932C21-0FFF-4909-9277-665E02DD6FE6Q39406092-0F38C71E-EE3B-43E8-B488-1E5F0896FD1EQ42351659-336707A0-9B4C-49FC-878D-3EAA8E457A65Q42557366-3A04400A-9789-4473-B804-E7CB2DA850F7Q44019603-9A215021-B70C-4701-A09C-CF5E6BE408B1Q44701500-E473A2DF-822F-4941-93DE-35DE35EFAFB7Q46358056-BA692A34-4B7E-4232-896B-FFDB0ED4EA03Q48273553-2161BA8B-A7B2-4C49-A48F-87CF4B97B3DD
P2860
Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Pharmacodynamics-mediated drug ...... miplostim in healthy subjects.
@ast
Pharmacodynamics-mediated drug ...... miplostim in healthy subjects.
@en
Pharmacodynamics-mediated drug disposition
@nl
type
label
Pharmacodynamics-mediated drug ...... miplostim in healthy subjects.
@ast
Pharmacodynamics-mediated drug ...... miplostim in healthy subjects.
@en
Pharmacodynamics-mediated drug disposition
@nl
prefLabel
Pharmacodynamics-mediated drug ...... miplostim in healthy subjects.
@ast
Pharmacodynamics-mediated drug ...... miplostim in healthy subjects.
@en
Pharmacodynamics-mediated drug disposition
@nl
P2093
P2860
P1433
P1476
Pharmacodynamics-mediated drug ...... miplostim in healthy subjects.
@en
P2093
Andrew T Chow
Jim J Xiao
Juan Jose Pérez-Ruixo
Sameer Doshi
Wojciech Krzyzanski
Yow-Ming C Wang
P2860
P2888
P304
P356
10.1208/S12248-010-9234-9
P407
P577
2010-10-21T00:00:00Z
P5875
P6179
1003078368